US Patent

US9925234 — Vasopressin formulations for use in treatment of hypotension

Method of Use · Assigned to Par Pharmaceuticals Inc · Expires 2035-01-30 · 9y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects peptide formulations that use polymers as stabilizing agents to decrease degradation of the peptides.

USPTO Abstract

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

Drugs covered by this patent

vasopressin (VASOPRESSIN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1857`	—	vasopressin
`U-1857`	—	vasopressin
`U-1857`	—	vasopressin
`U-1857`	—	vasopressin

Patent Metadata

Patent number: US9925234
Jurisdiction: US
Classification: Method of Use
Expires: 2035-01-30
Drug substance claim: No
Drug product claim: No
Assignee: Par Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.